The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers. The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however, a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted patients.
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) / Russo, D.; Polverelli, N.; Malagola, M.; Farina, M.; Leoni, A.; Bernardi, S.; Mammoliti, S.; Sacchi, N.; Martino, M.; Ciceri, F.; Zallio, F.; Olivieri, A.; Falcioni, S.; Storti, G.; Michieli, M.; Carluccio, P.; Grassi, A.; Oldani, E.; Bonifazi, F.; Prete, A.; Cavattoni, I. M.; Maffeis, M.; Pastore, D.; Vacca, A.; Caravelli, D.; Mirabile, M.; Mordini, N.; Nozzoli, C.; Faraci, M.; Federico, V.; Ronconi, S.; Skert, C.; Onida, F.; Marcatti, M.; Piemontese, S.; Narni, F.; Balduzzi, A.; De Simone, G.; Picardi, A.; De Gobbi, M.; Calore, E.; Tringali, S.; Zecca, M.; Secondino, S.; Guiducci, B.; Pelosini, M.; Zuffa, E.; Facchini, L.; Imola, M.; Iori, A. P.; Proia, A.; Sica, S.; Armiento, D.; Carella, A. M.; Dellacasa, C. M.; Fagioli, F.; Rabusin, M.; Ferrario, A.; Elice, F.. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 56:9(2021), pp. 2272-2275. [10.1038/s41409-021-01287-w]
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)
Martino M.;Ciceri F.;
2021-01-01
Abstract
The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers. The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however, a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
